Early identification of kidney disease cost-effective only when directed at high-risk patients

December 16, 2003

Routine annual testing for abnormally high levels of protein in the urine - an early marker of kidney malfunction and premature death - should be limited to those with other risk factors and older Americans, a Johns Hopkins study indicates.

"Given the relatively inexpensive and safe nature of urine testing for proteinuria, physicians might assume that frequent screening is something worth doing for everyone, but that's probably not true," says L. Ebony Boulware, M.D., M.P.H., lead study author and assistant professor of medicine at Hopkins. "Our results show that for the majority of the U.S. population -- those without hypertension or diabetes -- annual screening can actually be quite costly and anxiety producing for patients if you factor in false positive or negative test results, and the subsequent tests they may require. Screening should be directed at people with substantial risk of developing kidney disease, or it should be performed on a less frequent basis, such as every 10 years."

In the Hopkins report, published in the Dec. 17 issue of The Journal of the American Medical Association, the investigators recommend that annual screening be limited to hypertensive patients age 30 and up, and adults age 60 and up.

Chronic kidney disease is a growing public health problem that contributes to high health care costs, the authors note. More than 10 million Americans have some kidney damage and more than 300,000 have end-stage renal disease, a number estimated to double by 2010. With no set guidelines for the urine screening test, physicians have varied in whether and how they check patients for early kidney disease.

"Patients should be aware of their potential risk of kidney disease, and ask their physicians if they should be tested, particularly if they have diabetes or hypertension, or are at least age 60," says senior study author Neil R. Powe, M.D., M.P.H., director of Johns Hopkins' Welch Center for Prevention, Epidemiology and Clinical Research. "Physicians should understand which patients warrant periodic testing and subsequent treatment."

Boulware, Powe and colleagues assembled population data from the third National Health and Nutrition Examination Survey (NHANES III) and death statistics from a national mortality data file, then used that information to develop a computer program comparing the effectiveness of annual screening -- or no screening -- for proteinuria at different yearly intervals among hypothetical groups of healthy individuals and those with hypertension.

The screening strategy consisted of a urine test for proteinuria during an annual visit with a primary care physician. If results were positive, patients visited their doctor again for further testing, and if necessary, were referred to a kidney specialist or were prescribed medications such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin II-receptor blockers (ARB) to slow the progression of kidney disease and lower the incidence of heart attacks and other problems.

In the no-screening strategy, patients did not undergo routine screenings, but those who had natural progression of kidney disease may have been screened by their physicians as symptoms occurred. Screening of all study patients occurred annually until age 75, or until they developed end-stage renal disease or died.

The research team's analysis found that to save one year of "high-quality" life (called a "quality-adjusted life-year" or QALY) among the general population would cost $282,818. Ratios of $50,000 to $100,000 per QALY are thought to be more reasonable in decisions about mass screening. Screening everyone resulted in 135 invasive kidney biopsies, seven complications from biopsies and complication costs of $9,116, but the prevention of only one new case of end-stage renal disease and seven deaths per 1 million people per year.

However, for those with hypertension, screening proved highly favorable, at a cost of $18,621 per QALY. Such screening resulted in 196 kidney biopsies, seven complications from biopsies and complication costs of $200,000, with the prevention of approximately 14 new cases of end-stage renal disease and 104 deaths per million people per year.

"Physicians must incorporate a variety of considerations into decisions regarding early disease detection," Boulware adds. "When taking into account the kidney disease-slowing benefits for people with neither hypertension nor diabetes, who have low incidence and prevalence of proteinuria, regular screening averts very few ESRD cases and prevents few deaths. The resulting minimal gain in QALYs is too small to balance the costs of such testing."

The study also found that urine protein testing in the general population became more cost-effective when annual screening was initiated at age 60, at a cost of $53,372 per QALY. In addition, screening also made financial sense when done every 10 years. The estimated costs were $80,700 per QALY at age 50, $6,195 per QALY at age 60 and $5,486 per QALY at age 70.

Continuing research will use the computer program to look at the cost-effectiveness of screening other populations, such as African Americans (who have high rates of hypertension and diabetes), and to study other factors in kidney disease management, Boulware says.
-end-
The study was supported by the National Kidney Foundation of Maryland; the National Institute of Diabetes and Digestive and Kidney Diseases; and the Robert Wood Johnson Minority Faculty Development Program. Coauthors were Bernard G. Jaar, M.D., M.P.H.; Michelle E. Tarver-Carr, Ph.D.; and Frederick L. Brancati, M.D.

Boulware, L.E. et al, "Screening for Proteinuria in U.S. Adults: A Cost-effectiveness Analysis," The Journal of the American Medical Association, Dec. 17, 2003; Vol. 290, No. 23.

Johns Hopkins' Welch Center for Prevention, Epidemiology and Clinical Research http://www.med.jhu.edu/welchcenter/

The Journal of the American Medical Association: http://jama.ama-assn.org/

Johns Hopkins Medical Institutions' news releases are available on an EMBARGOED basis on EurekAlert at http://www.eurekalert.org and from the Office of Communications and Public Affairs' direct e-mail news release service. To enroll, call 410-955-4288 or send e-mail to bsimpkins@jhmi.edu.

On a POST-EMBARGOED basis find them at http://www.hopkinsmedicine.org

Johns Hopkins Medicine

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.